Contents

22 Zoster (herpes zoster/shingles)

References

  1. Gilden D. 2011. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. Journal of Internal Medicine 269(5): 496–506.
  2. Gershon A, Takahashi M, Seward JF. 2013. Varicella vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  3. Wehrhahn MC, Dwyer DE. 2012. Herpes zoster: epidemiology, clinical features, treatment and prevention. Australian Prescriber 35(5): 143–7.
  4. Carville KS, Riddell MA, Kelly HA. 2010. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 28(13): 2532–8.
  5. Leung J, Harpaz R, Molinari N-A, et al. 2011. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clinical Infectious Diseases 52(3): 332–40.
  6. Poletti P, Melegaro A, Ajelli M, et al. 2013. Perspectives on the impact of varicella immunization on herpes zoster. a model-based evaluation from three European countries. PLOS ONE 8(4). DOI: 10.1371/journal.pone.0060732 (accessed 25 November 2013).
  7. Reynolds MA, Chaves SS, Harpaz R, et al. 2008. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. Journal of Infectious Diseases 197(Suppl 2). DOI: 10.1086/522162 (accessed 24 November 2013).
  8. Hales C, Harpaz R, Joesoef R, et al. 2013. Examination of links between herpes zoster incidence and childhood varicella vaccination. Annals of Internal Medicine 159(11): 739–45.
  9. Oxman M, Levin M, Johnson G, et al. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in adults. New England Journal of Medicine 352(22): 2271–84.
  10. Langan SM, Smeeth L, Margolis DJ, et al. 2013. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLOS Med 10(4). DOI: 10.1371/journal.pmed.1001420 (accessed 8 October 2013).
  11. Schmader KE, Oxman MN, Levin MJ, et al. 2012. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical Infectious Diseases 55(10): 1230–8.
  12. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL: www.health.govt.nz/publication/national-guidelines-vaccine-storage-and-distribution-2012
  13. Tseng HF, Smith N, Sy LS, et al. 2011. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29(20): 3628–32.
  14. Centers for Disease Control and Prevention. 2013. Herpes Zoster Vaccination Information for Health Professionals. URL: www.cdc.gov/vaccines/vpd-vac/shingles/hcp-vaccination.htm (accessed 13 September 2013).
  15. Tseng HF, Liu A, Sy L. 2012. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. Journal of Internal Medicine 271(5): 510–20.
  16. Baxter R, Tran TN, Hansen J, et al. 2012. Safety of Zostavax™ – a cohort study in a managed care organization. Vaccine 30(47): 6636–41.